Abstract
The recent identification of techniques both in the mouse and in man to culture dendritic cells which could be adoptively trasnferred for therapy have opened new avenues of research. We have applied both synthetic and natural or acid eluted peptides from the tumor cell surface in order to elicit effective antitumor responses in vivo and in vitro in murine tumor models as well as in vivo in human preclinical trials. Based on these studies, we will soon initiate a human clinical trial utilizing human dendritic cells pulsed with synthetic melanoma derived peptides presented by HLA-A2. The delivery of genes into human dendritic cells to constitutively express cytokines, costimulatory molecules or tumor antigens represents another potential approach to the development of dendritic cell based therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Robbins PF, El-Gamil M, Kawakami, Y, Rosenberg SA. Recognition of tyrosinase by tumor - infiltrating lymphocytes from a patient responding to immunotherapy. 1994; Cancer Res 54:3124–3126.
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakkaguchi K, Appella E, Yanelli JR, Adema GJ, Kimi T, Rosenberg SA. Identification of melanoma antigens recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. 1994; Proc Natl Acad Sci 91: 6458–6462.
Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van Den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. 1991; Science 254: 1643–1047.
Traversari C, van der Bruggen P, Luescher IF, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-Al by cytolytic T–lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992: 176: 1453–1458
Van der Bruggen P, Szikora J-P, Boel, P, Wildmann C, Somville, M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*16018. 1994. Eur J Immunol 24: 2134–2140.
Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA. Differential expression of MAGE-1, -2, -3 messenger RNA in transformed and normal cell lines. 1993; Cancer Res 53: 54–47.
Shamamian P, Mancini M, Kawakami Y, et al.: Recognition of neuroectodermal tumors by melanoma -specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunol Immunother 1994; 39: 73–79
Gaugler B, Van den Eynde B, van der Bruggen P. Romerao P, Gaforio J J, De Plaen E, Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. 1994; J Exp Med 179: 921–930.
Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P. De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. 1994. Eur J Immunol 24: 3038–3043.
Boel-P; Wildmann-C; Sensi-ML; Brasseur-R; Renauld-JC; Coulie-P; Boon-T; van-der-Bruggen-P BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. 1995. Immunity. 2: 167–75
Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689–698, 1995.
Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen, E. Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA- A2 melanomas. 1993; J Exp Med 178: 489–495.
Wolfel T. Van Pel, A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K-H, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. 1994; Eur J Immunol 24: 759–764.
Wang R-F, Robbins PF, Kawakami Y, Kang X-Q, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31–restricted tumor–infiltrating lymphocytes. 1995; J Exp Med 181: 799–804.
Wang R-F, Robbins PF, Kawakami Y, Rosenberg SA. A novel human cancer antigen resulting from translation of an alternative open reading frame of TRP-I. Science, in press.
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding fora shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. 1994; Proc Natl Acad Sci 91: 3515–3519.
Coulie PG, Brichard V, VanPel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J-P, Renauld J-C, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. 1994; J Exp Med 180: 35–42.
Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally–processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. 1995; J Exp Med 181: 363–368.
Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. Melanocyte lineage–specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. 1994; J Exp Med 179: 1005–1009.
Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL. Identification of a peptide recognized by five melanoma–specific human cytotoxic T cell lines. 1994; Science 264: 716–719.
Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. 1993. J Exp Med 177: 265–272.
Egner W, McKenzie JL, Smith SM, Beard ME, Hart DN. Identification of potent mixed leukocyte reaction-stimulatory cells in human bone marrow. Putative differentiation stage of human blood dendritic cells. Journal of Immunology 1993; 150: 3043–3053.
Inaba K., Witmer-Pack M., Inaba M. et al. The tissue distribution of B7–2 costimulator in mice:abundant expression of dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180: 1849–1860, 1994.
Kämpgen, Koch F, Heufler C, Eggert A, Gill LL, Gillis S, Dower SK, Romani N, Schuler G. Understanding the dendritic cell lineage through a study of cytokine receptors. Journal of Experimental Medicine 1994; 179: 1767–1776.
Zhou L-J, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 1995; 86: 3295–3301.
Turcovski-Corrales SM, Fenton RG, Peitz G. Taub DD. CD28:B7 interactions promote T cell adhesion. European Journal of Immunology 1995; 25: 3087–3093.
Péguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, Van Kooten C, Banchereau J. Schmitt D. Functional expression of CD40 antigen on human epidermal Langerhans cells. Journal of Immunology 1995; 155: 4241–4247.
Young JW, Inaba K. Dendritic cells as adjuvants for class 1 major histocompatibility complex-restricted antitumor immunity. Journal of Experimental Medicine 1996; 183: 7–11.
Paglia P, Chiodoni C, Rodolfo M, Colombo MR Murine dendritic cells loaded in vitro iwth soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. Journal of Experimental Medicine 1996; 183: 317–322.
Knight SC, Hunt R, Dore C, Medawar PB. Influence of dendritic cells on tumor growth. Proceedings of the National Academy of Science 1985; 82: 4495–4497.
Mayordomo, J.1., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., lldstad, S.T., Kast, W.M., DeLeo, A., and Lotze, M.T. Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. 1: 1297–1302, 1995.
Celluzzi, C.M., Mayordomo, J.I., Stookus, W.J., Lotze, M.T., and Falo, L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183: 283–288, 1996.
Flamand, V. Murine Dendritic Cells Pulsed In Huy) with Tumor Antigen Induce Tumor Resistance In Vivo, Eur: J. Immunol. 23: 605–610, 1994.
Zitvogel, L., J. I. Mayordomo, T.Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-associated cytokines.J. Exp. Med. 183: 87–97.
Zou J-P, Shimizu J, Ikegame K, Takiuchi H, Fujiwara H, Hamaoka T. Tumor-immuotherapy with the use of tumor-antigen-pulsed antigen-presenting cells. Cancer Immunology Immunotherapy 1992; 35: 1–6.
Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 259: 1409–1410, 1993.
Georgopoulos C and Welch WJ. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 9: 601–634, 1993.
Mariethoz E, Tacchini-Cottier F, Jacquier-Sarlin M, Sinclair F and Polla BS. Exposure of monocytes to heat shock does not increase class II expression but modulates antigen-dependent T cell responses. Int Immunol 6: 925–930, 1994.
Polla BS and Mariethoz E. More evidence for a case for chaperones in antigen processing. Immunol Today 13: 421–422, 1992.
Suto R and Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585–1588, 1995.
Pierce SK. Molecular chaperones in the processing and presentation of antigen to helper T cells. Experientia 50: 1026–1030, 1994.
Kaur 1, Voss SD, Gupta RS, Schell K, Fisch P and Sonde! PM.. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt’s lymphoma cells.J Immunol: 2046–2055, 1993.
Mazzarella RA and Green M. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem 262: 8875–8883, 1987.
Booth C and Koch GLE. Perturbation of cellular calcium induces secretion of luminal ER proteins. Cell 59: 729–737, 1989.
Van Kaer L, Ashton-Rickardt PG, Ploegh HL and Tonegawa S. TAPI mutant mice are deficient in antigen presentation, surface class I molecules, and CD4–8+ T cells. Cell 71: 1205–1214, 1991.
Li Z and Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J 12: 3143–3151, 1993.
Levy F, Gabathuler R, Larsson R and Kvist S. Cell 67: 265–274, 1991.
Jacquier-Sarlin MR, Fuller K, Dinh-Xuan AT, Richard M-J and Polla BS. Protective effects of hsp70 in inflammation. Experientia 50: 1031–1038, 1994.
Udono H and Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178: 1391–1396, 1993.
Udono H, Levey DL and Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 91: 3077–3081, 1994.
Vanbuskirk A, Crump BL, Margoliash E and Pierce SK. A peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family. J Exp Med 170: 1799–1809, 1989.
Udono H and Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152: 5398–5403, 1994.
Arnold D, Faath S, Rammensee H-G and Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 182: 885–889, 1995.
Srivastava PK, Udono H, Blachere NE and Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93–98, 1994.
Tsujitani S, Oka A, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Infiltration of dendritic cells into regional lymph nodes in gastric cancer. Cancer 1995; 75 (6 Suppl): 1478–1483.
van Heerden WF, Raubenheimer EJ, van Rensburg EJ, le Roux R. Lack of correlation between DNA ploidy. Langerhans cell population and grading in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine 1995; 24 (2): 61–65.
Schreiner TU, Lischka G, Schaumburg-Lever G. Langerhans’ cells in skin tumors. Archives of Dermatology 1995; 131 (2): 187–190.
Zeid NA, Muller HK. Tobacco smoke condensate cutaneous carcinogenesis: changes in Langerhans’ cells and tumor regression. International Journal of Experimental Pathology 1995;76(1)75:83.
Viac J, Schmitt D, Claudy A. TNF alpha expressing cells in epidermal tumors: correlation with ICAM-I induction on keratinocytes and Langerhans cell distribution. In Vivo 1994; 8 (2): 221–225.
Alavaikko MJ, Blanco G, Aine R, Lehtinen T, Felbaum C, Taskinen PJ, Sarpola A, Hansmann ML. Follicular dendritic cells have prognostic relevance in Hodgkin’s disease. American Journal of Clinical Pathology 1994; 101 (6): 761–767.
Girod SC, Kuhnast T, Ulrich S, Krueger GR. Langerhans cells in epithelial tumors and benign lesions of the oropharynx. In Vivo 1994; 8 (4): 543–547.
Srivastava BI, Srivastava A, Srivastava MD. Phenotype, genotype and cytokine production in acute leukemia involving progenitors of dendritic Langerhans’ cells. Leukemia Research 1994; 18 (7): 499–511.
Kerrebijn JD, Balm AJ, Knegt PP, Meeuwis CA, Drexhage HA. Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma: an immunohistochemical study. Cancer Immunology, Immunotherapy 1994; 38 (1): 31–37.
Chan JK, Tsang WY, Ng CS, Tang SK, Yu HC, Lee AW. Follicular dendritic cell tumors of the oral cavity. American Journal of Surgical Pathology. 1994; 18 (2): 148–157.
Zeid NA, Muller HK. 5100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25 (4): 338–343.
Anonymous. Anticancer activity of dendritic cells. Symposium proceedings of the 4th International Conference of Anticancer Research. Crete. In Vivo 1993; 7 (3): 185–313.
Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993; 7 (3): 187–191.
Lmai Y, Yamakawa M. Dendritic cells in esophageal cancer and lymph node tissues. In Vivo 1993;7(31:239–248.
Yamakawa M, Kato H, Takagi S, Karube Y, Seki K, Imai Y. Dendritic cells in various human thyroid diseases. In Vivo 1993; 7 (3): 249–256.
Tsujitani S, Kakeji Y, Maehara Y, Sugimachi K, Kaibara N. Dendritic cells prevent lymph node metastasis in patients with gastric cancer. In Vivo 1993; 7 (3): 233–237.
Kessler II. Epidemiological considerations in the role of dendritic/Langerhans cells in human cancer. In Vivo 1993; 7 (3): 305–312.
Meissner K, Loning T, Rehpenning W. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sezary syndrome. In Vivo 1993; 7 (3): 277–280.
Muller HK. Dandle GW, Ragg SI, Woods GM. Langerhans cell alterations in cutaneous carcinogenesis. In Vivo 1993; 7 (3): 293–296.
van Rensburg EJ, van Heerden WF, Raubenheimer EJ. Langerhans cells and human papillomaviruses in oesophageal and laryngeal carcinomas. In Vivo 1993,731:229–232.
Fink-Puches R, Smolle J. Langerhans cells in epithelial skin tumors. A quantitative immunohistological and morphometric investigation. In Vivo 1993; 7 (3): 213–216.
Austyn JM. The dendritic cell system and anti-tumor immunity. In Vivo 1993; 7 (3): 193–201
Toriyama K, Wen Dr, Paul E, Cochran AJ. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. Journal of Investigative Dermatology 1993;100(3)269S–273S.
Tazi A, Bouchonnet F, Granssaigne M, Boumsell L. Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. Journal of Clinical Investigation 1993;91(2):566 576.
Spinollo A. Tenti P, Zappatore R, DeSeta F, Silini E, Guaschino S. Langerhans’ cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection. Gynecologic Oncology 1993; 48 (2): 210–213.
Morelli AE, Sananes C, DiPaola G, Paredes A, Fainboim L. Relationship between types of human papillomavirus and Langerhans’ cells in cervical condyloma and intraepithelial neoplasia. American Journal of Clinical Pathology. 1993; 99 (2): 200–206.
Drexhage HA. Mooy R, Jansen A, Kerregijn J. Allaerts W, Tas MP. Dendritic cells in tumor growth and endocrine diseases. Advances in Experimental Medicine and Biology. 1993; 329: 643–650.
Tas MP, Simons PJ, Balin FJ, Drexhage HA. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer immunology, Immunotherapy 1993: 36 (2): 108–114.
Koretz K, Moller P, Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumor cells. European Journal of Cancer 1993;29A(8):í 184–1189.
Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimaghi K. Infiltration of S-100 protein positive dendritic cells and peritoneal recurrence in advanced gastric cancer. International Surgery 1992: 77 (4): 238–241.
Fivenson DP, Beck ER, Dunstan RW, Nickoloff BJ, Moore PF. Dermal dendrocytes and I-cells in canine mycosis fungoides. Support for an animal model of human cutaneous T-cell lymphoma. Cancer 1992;70(8):2091–2098.
Regezi JA, Nickoloff B.l, Headington JT. Oral submucosal dendrocytes: factor XII la+ and CD34+ dendritic cell population in normal tissue and fibrovascular lesions. Journal of Cutaneous Pathology 1992;19(5):398–406.
Tsujitani S. Kakeji Y, Orita H, Watanabe A, Kohnoe S. Baba H, Anai H, Machara Y, Sugimachi K. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Research 1992;12(3)1645–648.
Morelli AE, Ronchetti RD. Secchi AD, Cufre MA, Paredes A, Fainboim L. Assessment by planimetry of Langerhans’ cell density in penile epithelium with human papillomavirus infection: changes observed after topical treatment. Journal of Urology 1992; 147 (5): 1268–1273.
Stene MA. Holthoj-Asnong C, Cochran AJ. Effect of epidermal Langerhans cells from melanoma patients on lymphoproliferative responses. Melanoma Research 1992;2(1):57–62.
Daniels TE, Chou L, Greenspan JS, Grady DG, Hauch WW, Greene JC, Ernster VL. Reduction of Langerhans cells in smokeless tobacco-associated oral mucosal lesions. Journal of Oral Pathology and Medicine 1992;21(3):100 104.
Nakano T, Oka K, Takahashi T, Moria S, Arai T. Roles of Langerhans’ cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer 1992; 70 (I 2): 2839–2844.
Bergfelt L, Larko O, Lindberg M. Density and morphology of Langerhans cells in basal cell carcinomas of the face and trunk. British Journal of Dermatology 1992; 127 (6): 575–579.
Papadimitriou CS, Datseris G, Costopoulos JS, Bai MK, loachim-Velogianni E, Katsouyannopoulos V. Langerhans cells and lymphocyte subsets in human gastrointestinal carcinomas. An immunohistological study on frozen sections. Pathology, Research and Practice. 1992; 188 (8): 989–994.
Kumar D, Sanchez RL, Kumar S. Dendrocyte population in cutaneous and extracutaneous Kaposi’s sarcoma. American Journal of Dermatopathology 1992; 14 (4): 298–303.
Tosi P, Sforza V, Santopietro R, Lio R, Gotti G, Paladini P, Cevenini G, Barbini P. Bronchiolo-alveolar carcinoma: an analysis of survival predictors. European Journal of Cancer 1992; 28A (8–9): 1365–1370.
Morelli AE, di Paola G, Fainboam L. Density and distribution of Langerhans cells in the human uterine cervix. Archives of Gynecology and Obstetrics 1992; 252 (2): 65–71.
Furihata M, Ohsuki Y, Ido E, Iwata J, Sonobe H, Araki K, Ogoshi S, Ohmori K. HLA-DR antigen-and 5100 protein-positive dendritic cells in esophageal squamous cell carcinoma–their distribution in relation to prognosis. Virchows Archiv. B. Cell Pathology Including Molecular Pathology 1992; 61 (6): 409–414.
Gallo O, Bianchi S, Giannini A, Gallina E, Libonati GA, Fini-Storchi O. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope 1991; 101 (5): 487–493.
Gomez-Morales M, Alvaro T, Munoz M. Garcia del Moral R, Aguilar D, Caballero T, Aneiros J. Diffuse sclerosing papillary carcinoma of the thyroid gland: immunohistochemical analysis of the local host immune response. Histopathology 1991; 18 (5): 427–433.
Wilson AJ, Maddoz PH, Jenkins D. CDIa and S100 antigen expression in skin Langerhans cells in patients with breast cancer. Journal of Pathology 1991; 163 (1): 25–30.
Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. Journal of Investigative Dermatology 1991; 97 (2): 197–202.
Bigotti G, Coli A, Castagnola D. Distribution of Langerhans cells and HLA class 11 molecules in prostatic carcinomas of different histopathological grade. Prostate 1991; 19 (1): 73–87.
Rucci L, Bani D, Gallo O, Arbi Riccardi R, Borghi Cirri MB, Fini-Storchi O. Interdigitating cells in the peritumoral infiltrate of laryngeal carcinomas: an immunocytochemical and ultrastructural study. Orl: Journal of Oto-Rhino-Laryngology and its Related Specialities. 1991;53(6):349356.
Scheicher C, Mehlig M, Dienes H-P, Reske K. Uptake of microparticle-absorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-la and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur. J. Immunol. 25: 1566–1572, 1995.
Jansen JH, Wientjens G-JHM, Fibbe WE, Willemze R, Kluin-Nelemans HC. Inhibition of human macrophage colony formation by interleukin 4. J. Exp. Med. 170: 577–582, 1989.
Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389–400, 1995.
Snyder DS, Beller Dl, Unanue ER. Prostaglandins modulate macrophage la expression. Nature 299: 163–165, 1982.
Gentile PS, Pelus LM. In vivo modulation of myelopoiesis by prostaglandin E2. 11.Inhibition of granulocyte-macrophage progenitor cell (CFU-GM) cycle rate. Exp. Hematol. 15:119–126, 1987.
Pelus LM, Ottmann OG, Nocka KH. Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by PgE and recombinant interferon-a, -ß, and -y and an effect mediated by tumor necrosis factor. J. Immunol. 140: 479–484, 1988.
Nussler AK, Billiar TR. Inflamation, immunoregulation, and inducible nitric oxide synthase. J. Leukoc. Biol. 54: 171–178, 1993.
Lu L, Bonham, Chambers F, Watkins S, Hoffman R, Simmons D, Thomson A. Induction of nitric oxide production by mouse dendritic cells in response to interferon-y, endotoxin and interaction with allogeneic T cells: Induction of nitric oxide synthase is associated with dendritic cell apoptosis. Submitted.
Inaba K, Steinmann RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursor in mouse blood. J. Exp. Med. 175:1157–1167, 1992(b).
Szabolcs P, Moore MAS, Ydung JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, GM-CSF, and TNF-a. J. Immunol. 154: 5851–5861, 1995.
Romani N., Gruner S., Brang D. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180: 83–93.
Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class 11 compartment: Downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389–400, 1995.
Galy A., Travis M., Cen D., Chen B. Human T, B, Natural Killer, and Dendritic Cells arise from a common bone marrow progenitor cell subset. Immunity 3: 459–471, 1995.
Maraskovsky E., Brasel K., Teepe M., Roux E., Shortman K., Lyman S.D., McKenna H.J. In vivo administration of flt3 ligand results in the generation of large numbers of dendritic cells in the lymphoid tissue of mice. In press.
Porgador A. and Gilboa, E. Bone-Marrow-Generated Dendritic Cells Pulsed with a Class I-Restricted Peptide are Potent Inducers of Cytotoxic T Lymphocytes, J. Exp. Med. 182: 255–260, 1995.
Grabbe, S. Tumor Antigen Presentation by Murine Epidermal Cells, J. Immunol. 146: 3656–3661, 1991.
Mayordomo, J.I., Loftus, D.J., Sakamoto, H., Lotze, M.T., Strokus, W.J., Appella, E., and DeLeo, A.B. THerapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183: 1357–1365, 1996.
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., and Storkus, W.J. Therapy of Murine Tumors with Tumor Peptide Pulsed Dependence on T-cells, B7 Costimulation, and Thl-Associated Cytokines, J. Exp. Med. 183: 87–98, 1996.
Kerrebijn, J.D., et al. Macrophage and Dendritic Cell Infiltration in Head and Neck Squamous-Cell Carcinoma; An Immunohistochemical Study, Cancer Immunol. Immunother: 38: 31–37, 1994.
Zeid, N.A. and Muller, H.K. S100 Positive Dendritic Cells in Human Lung Tumors Associated with Cell Differentiation and Enhanced Survival, Pathol. 25: 338–343, 1993.
Gallo, O., et al. Langerhans Cells Related to Prognosis in Patients with Larygeal Carcinoma, Arch. Otolaryngol. 117: 1007–1010, 1991.
Giannini, A., et al. Prognostic Significance of Accessory Cells and Lymphocytes in Nasopharygeal Carcinoma. Pathol. Res. Pract. 187: 486–502, 1991.
Tjandrawan, T., Macurer, M.i., Castelli, C., Lotze, M.T., and Storkus, W.J. Autologous Dendritic Cells Pulsed with MART-1/Melan-A, gp100. tyrosinase, or MAGE-3 Peptides Elicit Anti-Melanoma CTL From both Normal Donor and Cancer Patient Peripheral Blood Lymphocytes In Vitro. Submitted for publication. 1996.
Hsu, F.J., Benike, C., Franjoli, F.. Lilies, T.M., Tzerwinsky, T., et al. Vaccination of patients with 13 cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2: 52–55, 1996.
F. Sallusto and A. Lanzavecchia, Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells is Maintained by Granulocyte/Macrophage Colony-Stimulating Factor Plus Interleukin 4 and Down-regulated by Tumor Necrosis Factor Alpha, J. Exp. Med. 179: 1109–1118, 1994.
Romani, N., Gruner. S., Brang, D., Kampgen, E., Lenz, A., et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180: 83–93, 1994.
Bakker, A.B., Marland, G., De Boer, A.J., Danen, H., Adema, G.J., and Figdor, C.G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55: 5330–5339, 1995.
Storkus, W.J., and Lotze, M.T. Biology of Tumor Antigens: Tumor Antigens Recognized By Immune Cells. In: V. DeVita, S. Hellman, and S. Rosenberg (Eds.), Biologic Therapy of Cancer, 2nd. ed. J.B. Lippincott Company. Philadelphia. 1995. pp. 64–77.
Zitvogel, L., Couderc, B., Mayordomo, J.1., Robbins, P.D., Lotze, M.T., and Storkus, W.J. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. New York. Acad. Sci.,in press, 1996.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lotze, M.T., Shurin, M., Davis, I., Amoscato, A., Storkus, W.J. (1997). Dendritic Cell Based Therapy of Cancer. In: Ricciardi-Castagnoli, P. (eds) Dendritic Cells in Fundamental and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 417. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9966-8_91
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9966-8_91
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9968-2
Online ISBN: 978-1-4757-9966-8
eBook Packages: Springer Book Archive